PD-1/PD-L1-IN-9 is a potent and orally active inhibitor of PD-1/PD-L1, with an IC50 value of 3.8nM [1]. The aminoethanol tail of PD-1/PD-L1-IN-9 interacts with AAsp122 and BGln66 via two hydrogen bonds and contributes to the high binding affinity to dimeric PD-L1[1]. PD-1/PD-L1-IN-9 has been widely used to block inhibition of PD-1 reporter T cells[2].
In vivo, PD-1/PD-L1-IN-9 treatment via oral administration at a dose of 80mg/kg/day for 2 weeks significantly inhibited tumor growth in the CT26 mouse model[1].
References:
[1] Wang T, Cai S, Wang M, et al. Novel biphenyl pyridines as potent small-molecule inhibitors targeting the programmed cell death-1/programmed cell death-ligand 1 interaction[J]. Journal of Medicinal Chemistry, 2021, 64(11): 7390-7403.
[2] Leitner J, Schindler H, Gumpelmair S, et al. Evaluation of small molecule PD-1/PD-L1 inhibitors in a T cell reporter system[J]. Biochemical Pharmacology, 2026: 117871.
PD-1/PD-L1-IN-9是一种强效且口服有效的PD-1/PD-L1抑制剂,IC50值为3.8nM[1]。PD-1/PD-L1-IN-9的氨基乙醇尾部通过两个氢键与Asp122和Gln66相互作用,有助于与二聚体PD-L1的高结合亲和力[1]。PD-1/PD-L1-IN-9 已被广泛用于阻断 PD-1 报告T细胞的抑制作用[2]。
在体内,口服给予80mg/kg/day剂量的PD-1/PD-L1-IN-9治疗2周,显著抑制了CT26小鼠模型中的肿瘤生长[1]。
















